76Bio
76Bio is a privately-held, Delaware-incorporated biotechnology company founded in 2020 and based in New York, developing therapies for life-threatening diseases. The company has a small team and one disclosed ~$10M financing led by Polaris Partners.
- Company typePrivate
- Founded2020
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
76Bio firmographics
Firmographics- Name
- 76Bio
- Legal name
- 76Bio, Inc.
- Website
- https://76bio.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- 76Bio is a privately-held, Delaware-incorporated biotechnology company founded in 2020 and based in New York, developing therapies for life-threatening diseases. The company has a small team and one disclosed ~$10M financing led by Polaris Partners.
- Ownership category
- akta.pro rank
Where 76Bio is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
76Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
76Bio product offering
Product offeringCore offering
76Bio is a biotechnology company that develops therapies for patients with life-threatening diseases. Founded in 2020 and headquartered in New York, the company is a privately-held Delaware-incorporated entity conducting research-stage therapeutic development, with disclosed funding of over $10 million raised through an SEC Rule 506(b) exempt offering in January 2022.
Differentiator
Problem solved
Functional benefit
Companies that use 76Bio
Customer profileIdeal customer profiles1 record
76Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
76Bio partnerships and signals
Strategic signalScale indicators1 record
76Bio competitors and assessment
Company assessmentEmerging players
- Werewolf Therapeutics: Werewolf Therapeutics engineers conditionally activated biologic therapeutics for cancer. Comparable to 76Bio as a small-cap biotech applying protein engineering to develop disease-targeted therapies.
- Generate Biomedicines: Generate Biomedicines uses generative biology to engineer novel protein therapeutics. It overlaps with 76Bio on the premise that computational/synthetic biology can unlock new biologic modalities for serious diseases.
- Compass Therapeutics: Compass Therapeutics develops antibody-based therapeutics for oncology and autoimmune disease. It is comparable to 76Bio as a clinical-stage antibody therapeutics developer targeting serious diseases.
- Cullinan Oncology: Cullinan Oncology develops diversified oncology therapeutics with a multi-asset strategy. It is comparable to 76Bio as a small public biotech pursuing multiple biologic candidates against serious diseases.
- BigHat Biosciences: BigHat Biosciences combines ML with synthetic biology to design improved antibody therapeutics. It is comparable to 76Bio given the shared emphasis on engineering-design rather than empirical discovery of biologics.
- Paragon Therapeutics: Paragon Therapeutics is a recently formed biotech incubator/holding company developing engineered antibody therapeutics. It is structurally comparable to 76Bio as an early-stage vehicle for advanced biologics R&D.
Broad incumbents
- Regeneron Pharmaceuticals: Regeneron is a leading commercial biologics company with deep antibody engineering capabilities (VelocImmune, etc.). It contextualizes 76Bio within the broader engineered-antibody industry as the dominant scaled incumbent.
- Moderna: Moderna operates a large-scale biologics platform (mRNA and protein therapeutics). It is comparable as a Boston-area biotech with platform-based development of therapeutics for serious diseases.
- Adimab: Adimab is a well-established antibody discovery and engineering platform serving pharma partners. It is comparable to 76Bio given the shared scientific lineage around engineered biologics/antibodies and the founders' expertise in protein engineering.
Others
- Flagship Pioneering: Flagship Pioneering is a biotech venture creator that originates and funds platform therapeutics companies. It is comparable to 76Bio contextually as a generator/funder of early-stage therapeutic ventures with academic founders.
Market position
Customer concentration
76Bio social profiles
Digital presence76Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
76Bio leadership team
Management profileNumber of profiles
Profiles1 record
76Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
76Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 76Bio
What does 76Bio do?
76Bio is a biotechnology company that develops therapies for patients with life-threatening diseases. Founded in 2020 and headquartered in New York, the company is a privately-held Delaware-incorporated entity conducting research-stage therapeutic development, with disclosed funding of over $10 million raised through an SEC Rule 506(b) exempt offering in January 2022.
Is 76Bio a public or private company?
76Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was 76Bio founded?
76Bio was founded in 2020. It employs 11 to 50 people.
Where is 76Bio based?
76Bio is headquartered in New York, United States, in the North America region.
Who are 76Bio's main competitors?
Emerging players on record are Werewolf Therapeutics, Generate Biomedicines, Compass Therapeutics, Cullinan Oncology, BigHat Biosciences and Paragon Therapeutics. Broad incumbents are Regeneron Pharmaceuticals, Moderna and Adimab. Flagship Pioneering is listed as an others.
Does 76Bio have an API?
No public API is recorded for 76Bio.